Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares were up more than 10% in pre-market trading today after the biopharmaceutical company released positive trial results from the …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares rose more than +10% in pre-market trading to $32.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced the initiation of an open-label, Phase 1/2 safety and tolerability study examining the investigational combination of varlilumab and …
Celldex Therapeutics, Inc. (NASDAQ:CLDX), announced that several clinical programs, including the Phase 2 ReACT study of RINTEGA® (rindopepimut) in patients with recurrent glioblastoma (GBM), …
Brean Capital analyst Jonathan Aschoff came out with a few insights on Celldex Therapeutics (NASDAQ:CLDX) following the company’s first-quarter financial results and update on its …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the first quarter ended March 31, 2015.
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced preclinical results that further support varlilumab’s expansion into combination studies with PD-1 inhibitors.
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a price target of $43, after the company announced the initiation …
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in …
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced the initiation of a Phase 1/2 safety pilot and expansion study examining the investigational combination of varlilumab and …
